Mesa Laboratories (NASDAQ:MLAB) Given New $110. 00 Price Target at Wells Fargo & Company
Mesa Laboratories (NASDAQ:MLAB-Get Free Report)had its target price boosted by analysts atWells Fargo & Companyfrom $94. 00 to $110. 00 in a research note issued to investors on Friday,Benzingareports. The. . .
Mesa Laboratories (NASDAQ:MLAB-Get Free Report)had its target price boosted by analysts atWells Fargo & Companyfrom $94. 00 to $110. 00 in a research note issued to investors on Friday,Benzingareports. The brokerage currently has an "equal weight" rating on the medical instruments supplier's stock. Wells Fargo & Company's price objective indicates a potential downside of 1. 82% from the stock's previous close. Separately,Weiss Ratingsupgraded shares of Mesa Laboratories from a "sell (d)" rating to a "hold (c-)" rating in a research report on Tuesday. Three analysts have rated the stock with a Hold rating, According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $110. 00. GetMesa Laboratoriesalerts:Check Out Our Latest Stock Analysis on Mesa LaboratoriesMesa Laboratories Stock PerformanceShares ofMLAB stocktraded down $1. 16 on Friday, reaching $112. 04. The stock had a trading volume of 48,149 shares, compared to its average volume of 147,655. The firm's 50-day moving average is $100. 59 and its two-hundred day moving average is $95. 90. The firm has a market capitalization of $626. 97 million, a price-to-earnings ratio of 133. 36 and a beta of 0. 92. The company has a quick ratio of 1. 29, a current ratio of 1. 72 and a debt-to-equity ratio of 0. 78. Mesa Laboratories has a 12 month low of $58. 83 and a 12 month high of $115. 52. Mesa Laboratories (NASDAQ:MLAB-Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The medical instruments supplier reported $2. 68 earnings per share for the quarter. Mesa Laboratories had a return on equity of 22. 87% and a net margin of 1. 92%. The business had revenue of $60. 14 million for the quarter. Insider Buying and SellingIn other news, CFOJohn Sakyssold 2,827 shares of the firm's stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $89. 50, for a total value of $253,016. 50. Following the completion of the sale, the chief financial officer directly owned 19,785 shares in the company, valued at $1,770,757. 50. This trade represents a 12. 50% decrease in their position. The sale was disclosed in a filing with the SEC, which is available atthis link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAOLyndsey Elizabeth Crennensold 442 shares of the business's stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $89. 50, for a total value of $39,559. 00. Following the completion of the sale, the chief accounting officer directly owned 2,020 shares of the company's stock, valued at $180,790. The trade was a 17. 95% decrease in their ownership of the stock. The disclosure for this sale is available in theSEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 8,277 shares of company stock valued at $770,122 over the last ninety days. 2. 80% of the stock is owned by corporate insiders. Hedge Funds Weigh In On Mesa LaboratoriesLarge investors have recently modified their holdings of the company. Ranger Investment Management L. P. acquired a new position in Mesa Laboratories during the second quarter worth $17,321,000. Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in shares of Mesa Laboratories during the 2nd quarter valued at $15,507,000. Boston Partners lifted its stake in Mesa Laboratories by 2,009. 5% in the 3rd quarter. Boston Partners now owns 114,357 shares of the medical instruments supplier's stock worth $7,664,000 after purchasing an additional 108,936 shares in the last quarter. Millennium Management LLC increased its stake in Mesa Laboratories by 131. 9% in the 3rd quarter. Millennium Management LLC now owns 133,817 shares of the medical instruments supplier's stock worth $8,967,000 after acquiring an additional 76,107 shares during the last quarter. Finally, Wasatch Advisors LP raised its stake in Mesa Laboratories by 125. 8% in the second quarter. Wasatch Advisors LP now owns 115,668 shares of the medical instruments supplier's stock valued at $11,515,000 after purchasing an additional 64,435 shares in the last quarter. 90. 60% of the stock is currently owned by institutional investors. About Mesa Laboratories(Get Free Report)Mesa Laboratories,IncNASDAQ: MLABis a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes. The company's product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications. Featured ArticlesFive stocks we like better than Mesa LaboratoriesSandisk’s Margins Look Like Software. Can They Last?CAVA Earnings: The Easiest Comp of the Year Meets a Tough ValuationJoint Operations: Curaleaf Makes a Play for Aurora CannabisCerebras Sells Off After Earnings: Is This a Market Disconnection?This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat. com. Continue following MarketBeatAdd MarketBeat as your preferred source on Google to see our latest stories in your feed. Should You Invest $1,000 in Mesa Laboratories Right Now?Before you consider Mesa Laboratories, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified thefive stocksthat top analysts are quietly whispering to their clients to buy now before the broader market catches on. . . and Mesa Laboratories wasn't on the list. While Mesa Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks HereThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important. Get This Free Report